JPH0129765B2 - - Google Patents
Info
- Publication number
- JPH0129765B2 JPH0129765B2 JP55059080A JP5908080A JPH0129765B2 JP H0129765 B2 JPH0129765 B2 JP H0129765B2 JP 55059080 A JP55059080 A JP 55059080A JP 5908080 A JP5908080 A JP 5908080A JP H0129765 B2 JPH0129765 B2 JP H0129765B2
- Authority
- JP
- Japan
- Prior art keywords
- parts
- water
- hydrogel
- meth
- acrylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000017 hydrogel Substances 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 229940079593 drug Drugs 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 11
- 229920001577 copolymer Polymers 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 7
- 229920000647 polyepoxide Polymers 0.000 claims description 5
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 4
- 125000003700 epoxy group Chemical group 0.000 claims description 4
- 125000000524 functional group Chemical group 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- GYZLOYUZLJXAJU-UHFFFAOYSA-N diglycidyl ether Chemical group C1OC1COCC1CO1 GYZLOYUZLJXAJU-UHFFFAOYSA-N 0.000 claims description 2
- 238000012360 testing method Methods 0.000 description 13
- 239000000463 material Substances 0.000 description 9
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 229920003067 (meth)acrylic acid ester copolymer Polymers 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 229960001047 methyl salicylate Drugs 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- OUPZKGBUJRBPGC-UHFFFAOYSA-N 1,3,5-tris(oxiran-2-ylmethyl)-1,3,5-triazinane-2,4,6-trione Chemical compound O=C1N(CC2OC2)C(=O)N(CC2OC2)C(=O)N1CC1CO1 OUPZKGBUJRBPGC-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- -1 alkaline earth metal salt Chemical class 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- IVIDDMGBRCPGLJ-UHFFFAOYSA-N 2,3-bis(oxiran-2-ylmethoxy)propan-1-ol Chemical compound C1OC1COC(CO)COCC1CO1 IVIDDMGBRCPGLJ-UHFFFAOYSA-N 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- 229920000297 Rayon Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- ROOXNKNUYICQNP-UHFFFAOYSA-N ammonium persulfate Chemical compound [NH4+].[NH4+].[O-]S(=O)(=O)OOS([O-])(=O)=O ROOXNKNUYICQNP-UHFFFAOYSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000004745 nonwoven fabric Substances 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 2
- 239000002964 rayon Substances 0.000 description 2
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- UWFRVQVNYNPBEF-UHFFFAOYSA-N 1-(2,4-dimethylphenyl)propan-1-one Chemical compound CCC(=O)C1=CC=C(C)C=C1C UWFRVQVNYNPBEF-UHFFFAOYSA-N 0.000 description 1
- HDPLHDGYGLENEI-UHFFFAOYSA-N 2-[1-(oxiran-2-ylmethoxy)propan-2-yloxymethyl]oxirane Chemical compound C1OC1COC(C)COCC1CO1 HDPLHDGYGLENEI-UHFFFAOYSA-N 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- 229920001342 Bakelite® Polymers 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- ZJCCRDAZUWHFQH-UHFFFAOYSA-N Trimethylolpropane Chemical compound CCC(CO)(CO)CO ZJCCRDAZUWHFQH-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229910001870 ammonium persulfate Inorganic materials 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 229940033495 antimalarials Drugs 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 239000004637 bakelite Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- CQEYYJKEWSMYFG-UHFFFAOYSA-N butyl acrylate Chemical compound CCCCOC(=O)C=C CQEYYJKEWSMYFG-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000035597 cooling sensation Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000002788 crimping Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- XHIOOWRNEXFQFM-UHFFFAOYSA-N ethyl prop-2-enoate;prop-2-enoic acid Chemical compound OC(=O)C=C.CCOC(=O)C=C XHIOOWRNEXFQFM-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229920000578 graft copolymer Polymers 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001083 polybutene Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000002685 polymerization catalyst Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Description
この発明は身体面に直接或いは容器に封入され
た状態で接触させて、身体の種々の障害を除去す
るか或いは軽減する目的で使用される治療系に用
いられる架橋型含水ゲルに関するものであり、更
に詳しくは保水性が良好で、夏期の外気温の上昇
或いは身体に適用後の体温で軟化して変形した
り、離水したりすることがない架橋型含水ゲルを
提供するものである。
打撲、捻挫などの症状の治療或いは筋肉の凝り
を和らげる材料として種々の含水系材料が知られ
ている。例えば、カオリン、グリセリン及びゼラ
チン水溶液を混合したもの、或いは吸湿性のアル
カリ土類金属塩、ポリブテン、アラビヤゴム又は
ゼラチン、多価アルコール、水、カオリン及びベ
ントナイトを混合したものなどがある。
しかしてこれらの含水系材料は、その凝集力が
小さく泥状であるために、使用後身体面に残留し
たり、発汗によりさらに可塑化されてべとついた
りするといつた種々の問題がある。
近時かかる含水系材料を改善する目的で、該材
料に架橋性のポリマー例えばポリビニルアルコー
ル、ポリアクリル酸塩、セルロース系誘導体など
を添加すると共に、該ポリマーを架橋成分例えば
金属塩、ホウ砂、ポリイソシアネート化合物など
を用いて上記ポリマーを架橋する方法も提案され
ているが、未だ皮膚に対する密着性などが不充分
であるという問題がある。
この発明はこれらの欠点を解決し、しかも冷却
或いは冷感効果を提供する保水能力と、適用面に
対して密着する粘着性とを有する架橋型含水ゲル
に関するもので、特に治療系に格別の効果を発揮
する含水ゲルを提供するものである。
即ちこの発明は、ポリマー中にエポキシ基と反
応し得る官能基を有するアルキル基の炭素数が4
以下の(メタ)アクリル酸アルキルエステル系共
重合体と、水と、分子内に2個以上のグリシジル
エーテル基を含有するポリエポキシドとを必須成
分とし、治療を目的として貼付または被覆状態で
用いられる架橋型含水ゲルを提供するものであ
る。
この発明の含水ゲルは、多量の水分を保有する
こと、良好な保水及び保形性を有すること、好適
な粘着性を有すること、及び製造時加熱工程を必
ずしも必要としないことなどによつて特徴づけら
れ、さらに、例えば加熱工程を必要としないこと
による特徴は含水ゲル中に薬物が均一に分散又は
溶解されるように各成分を調合して含水ゲルを製
造しても、熱による薬物の分解、変質、揮散など
の好ましくない作用による薬物の損失がないとい
う、格別の効果を有する架橋型含水ゲルを提供す
ることができる。
この発明の実施に当たつて用いられる(メタ)
アクリル酸エステル系共重合体としては、ポリマ
ー中にエポキシ基と反応し得る官能基、例えばカ
ルボキシル基、ヒドロキシル基などを有する単量
体を(メタ)アクリル酸エステルと共重合して得
られる水溶性の共重合体の少なくとも一種、又は
該共重合体と相溶性が良好で揮散性の少ない水溶
性の可塑剤、例えばポリエーテルポリオールもし
くは多価アルコールなどの任意成分との混合物な
どが挙げられる。
上記(メタ)アクリル酸エステル系共重合体の
好適な例としては、(メタ)アクリル酸−(メタ)
アクリル酸エステル共重合体及びその誘導体、
(メタ)アクリルアミド−アクリロニトリル−(メ
タ)アクリル酸エステル共重合体及びその誘導体
などが挙げられる。なお、上記共重合体としてグ
ラフト重合物も使用することができる。
これらの(メタ)アクリル酸エステル系共重合
体は架橋型含水ゲルの固形分約20〜75重量%、好
ましくは30〜70重量%の範囲で使用することが望
ましく、約20重量%以下ではゲルの保形性に欠け
ると共に身体面に確実に適用されることができる
程の粘着又は密着性が得られにくく、75重量%以
上では保冷及び冷感効果が不充分となり、治療系
として好ましくないものである。
(メタ)アクリル酸エステル系共重合体と水と
の混合物には、物質中のエポキシ基と反応して該
物質を架橋せしめる架橋成分としてのポリエポキ
シドが配合され、架橋型含水ゲルが提供される。
該ポリエポキシドとしては、(ポリ)エチレン
グリコールジグリシジエーテル、(ポリ)プロピ
レングリコールジグリシジルエーテル、トリグリ
シジルイソシアヌレート、ジグリセリントリグリ
シジルエーテル、グリセリンジグリシジエーテ
ル、トリメチロールプロパンポリグリシジルエー
テルなどが挙げられ、これらは一種以上が前記
(メタ)アクリル酸エステル系共重合体に対して
0.05〜5重量%の割合で添加される。
このように構成してなる架橋型含水ゲルは、柔
軟な袋状物に封入するか或いは担持体上に形成さ
れ、身体の障害を除去又は軽減する治療系に用い
られる。
またこの発明の含水ゲルの最適用途の一つであ
る、疾患治療用に用いる場合には、該含水ゲルを
製造する適宜の段階で、目的に応じた薬物を初め
とする活性物質を所定量添加する。
この発明の架橋型含水ゲルは保冷及び冷感効果
に優れ、しかも保形性が良好であり、身体に適用
後は可塑化されてべとついたり、残留したりする
ことがないものである。また薬物を用いた系は、
上記の如き好適な含水ゲルの特性により、身体へ
の薬物の提供が確実で充分な薬効が得られる治療
系材料を提供する。
以下この発明の実施例を示す。文中部とあるの
は重量部を示す。
実施例 1
アクリル酸エチル100部、アクリル酸30部をエ
チルアルコール195部中で、0.3部の過硫酸カリウ
ムを重合触媒として、不活性ガス下で重合し(重
合温度60℃)、重合反応終了後、塩化ナトリウム
水溶液で中和し、水溶性物質としてのアクリル酸
エチル−アクリル酸共重合体ナトリウム塩を得
る。
次に該ナトリウム塩に水を添加して30%溶液と
し、この溶液の固型分100部に対して水溶性可塑
剤としてのポリオキシプロピル化ソルビトール
100部及びトリグリシジルイソシアヌレートの20
%水溶液10部を添加混合し、厚さ100μのレーヨ
ン不織布の表面に約1mmの厚さとなるように展延
して常温で架橋して、シート状の架橋型含水ゲル
を得る。
実施例 2
アクリル酸90部、アクリル酸ブチル10部、ポリ
オキシプロピル化ソルビトール50部、過硫酸アン
モニウム2部を水350部に溶解し、不活性ガス気
流中で60℃で8時間重合した。この様にして得ら
れた粘稠溶液100部にポリオキシプロピル化ソル
ビトール60部、20%水酸化カリウム水溶液30部、
10%トリグリシジルイソシアヌレート水溶液10部
を加え均一に混合した後、厚さ100μのレーヨン
不織布上に厚さ約1mmとなるように展延し、シー
ト状の架橋型含水ゲルを得る。
第1表に実施例1および2の試験結果を示す。
This invention relates to a cross-linked hydrogel used in a therapeutic system that is used for the purpose of removing or alleviating various disorders of the body by contacting it directly with the body surface or sealed in a container. More specifically, the purpose is to provide a crosslinked hydrogel that has good water retention properties and does not soften and deform due to increases in outside temperature in summer or body heat after being applied to the body, nor does it release water. Various water-containing materials are known as materials for treating symptoms such as bruises and sprains, and for relieving muscle stiffness. Examples include a mixture of kaolin, glycerin and an aqueous gelatin solution, or a mixture of a hygroscopic alkaline earth metal salt, polybutene, gum arabic or gelatin, polyhydric alcohol, water, kaolin and bentonite. However, since these water-containing materials have a low cohesive force and are muddy, they have various problems such as remaining on the body surface after use or becoming sticky due to plasticization due to perspiration. Recently, in order to improve such water-containing materials, crosslinkable polymers such as polyvinyl alcohol, polyacrylates, cellulose derivatives, etc. are added to the materials, and the polymers are combined with crosslinking components such as metal salts, borax, polyester, etc. Although a method of crosslinking the above-mentioned polymer using an isocyanate compound or the like has been proposed, there is still a problem that the adhesion to the skin is insufficient. The present invention solves these drawbacks and relates to a cross-linked hydrogel that has a water-retaining ability that provides a cooling or cooling effect and an adhesive property that adheres closely to the surface to which it is applied, and which is particularly effective in therapeutic systems. The present invention provides a hydrogel that exhibits the following properties. That is, this invention provides a polymer with an alkyl group having a functional group capable of reacting with an epoxy group having 4 carbon atoms.
A cross-linked product that contains the following (meth)acrylic acid alkyl ester copolymer, water, and a polyepoxide containing two or more glycidyl ether groups in its molecule as essential components, and is used in a pasted or covered state for therapeutic purposes. type hydrogel. The hydrogel of the present invention is characterized by holding a large amount of water, having good water retention and shape retention, having suitable adhesiveness, and not necessarily requiring a heating process during production. Furthermore, the feature of not requiring a heating process, for example, is that even if a hydrogel is manufactured by mixing each component so that the drug is uniformly dispersed or dissolved in the hydrogel, the drug does not decompose due to heat. It is possible to provide a crosslinked hydrogel that has an exceptional effect in that there is no loss of drug due to undesirable effects such as deterioration, volatilization, etc. Used in carrying out this invention (meta)
The acrylic ester copolymer is a water-soluble copolymer obtained by copolymerizing (meth)acrylic ester with a monomer having a functional group that can react with an epoxy group, such as a carboxyl group or a hydroxyl group, in the polymer. or a mixture of the copolymer with an optional component such as a water-soluble plasticizer having good compatibility with the copolymer and low volatility, such as a polyether polyol or a polyhydric alcohol. As a preferable example of the above (meth)acrylic acid ester copolymer, (meth)acrylic acid-(meth)
Acrylic ester copolymers and derivatives thereof,
Examples include (meth)acrylamide-acrylonitrile-(meth)acrylic acid ester copolymer and derivatives thereof. In addition, a graft polymer can also be used as the above-mentioned copolymer. It is desirable to use these (meth)acrylic acid ester copolymers in a solid content range of about 20 to 75% by weight, preferably 30 to 70% by weight of the crosslinked hydrogel. It lacks shape retention, and it is difficult to obtain sufficient adhesion or adhesion to ensure reliable application to the body surface, and if it exceeds 75% by weight, the cold retention and cooling effect will be insufficient, making it undesirable as a therapeutic system. It is. A polyepoxide as a crosslinking component that reacts with the epoxy groups in the substance to crosslink the substance is blended into the mixture of the (meth)acrylic acid ester copolymer and water to provide a crosslinked hydrogel. Examples of the polyepoxide include (poly)ethylene glycol diglycidyl ether, (poly)propylene glycol diglycidyl ether, triglycidyl isocyanurate, diglycerin triglycidyl ether, glycerin diglycidyl ether, trimethylolpropane polyglycidyl ether, and the like. One or more of these is based on the above (meth)acrylic acid ester copolymer.
It is added in a proportion of 0.05 to 5% by weight. The crosslinked hydrogel thus constituted is enclosed in a flexible bag-like material or formed on a carrier, and used in a therapeutic system for eliminating or alleviating physical disorders. In addition, when the hydrogel of this invention is used for disease treatment, which is one of the most suitable uses, a predetermined amount of active substances such as drugs according to the purpose is added at an appropriate stage of manufacturing the hydrogel. do. The crosslinked hydrogel of the present invention has excellent cold retention and cooling sensation effects, and also has good shape retention, and does not become plasticized and sticky or remain after being applied to the body. In addition, the system using drugs is
Due to the suitable properties of the hydrogel as described above, a therapeutic material is provided that ensures the delivery of the drug to the body and provides sufficient medicinal efficacy. Examples of this invention will be shown below. The words "part of the text" indicate parts by weight. Example 1 100 parts of ethyl acrylate and 30 parts of acrylic acid were polymerized in 195 parts of ethyl alcohol using 0.3 parts of potassium persulfate as a polymerization catalyst under an inert gas (polymerization temperature 60°C), and after the completion of the polymerization reaction. , and neutralized with an aqueous sodium chloride solution to obtain an ethyl acrylate-acrylic acid copolymer sodium salt as a water-soluble substance. Next, water is added to the sodium salt to make a 30% solution, and polyoxypropylated sorbitol as a water-soluble plasticizer is added to 100 parts of the solid content of this solution.
100 parts and 20 parts of triglycidyl isocyanurate
% aqueous solution is added and mixed, spread on the surface of a 100μ thick rayon nonwoven fabric to a thickness of about 1 mm, and crosslinked at room temperature to obtain a sheet-shaped crosslinked hydrogel. Example 2 90 parts of acrylic acid, 10 parts of butyl acrylate, 50 parts of polyoxypropylated sorbitol, and 2 parts of ammonium persulfate were dissolved in 350 parts of water, and polymerized at 60° C. for 8 hours in an inert gas stream. To 100 parts of the viscous solution thus obtained, 60 parts of polyoxypropylated sorbitol, 30 parts of 20% potassium hydroxide aqueous solution,
After adding 10 parts of a 10% triglycidyl isocyanurate aqueous solution and mixing uniformly, the mixture is spread on a 100 μm thick rayon nonwoven fabric to a thickness of about 1 mm to obtain a sheet-like crosslinked hydrogel. Table 1 shows the test results of Examples 1 and 2.
【表】
第1表中比較例1および2は、実施例1および
2の配合において用いた架橋成分としてのポリエ
ポキシドを加えなかつたものである。また参考例
1は、ゼラチン15部、ポリアクリル酸ソーダ4部
(平均重合度30000〜66000)、グリセリン10部、水
36部、サリチル酸メチル2部、dl−カンフア−2
部、l−メントール1部にグリセリンジグリシジ
ルエーテル2部からなる含水系材料であり、参考
例2はカルボキシメチルセルロースナトリウム
4.8部メチルセルロース2.4部、ポリアクリル酸ソ
ーダ3.8部、ゼラチン5.9部、グリセリン35.6部・
水47.5部、l−メントール1.3部、dl−カンフア−
1部、サリチル酸メチル2部、チモール1.2部か
らなる含水系材料である。
第1表中の試験方法
90度剥離接着力:試験ゲルシートより巾5cm、
長さ約20cmの試験片を3枚とり、表面をエチルア
ルコールで充分洗浄したベークライト板に含水ゲ
ル面を重ね合せ、850gの圧着ロールを300mm/
minの速さで一往復して圧着し、30分間放置した
後、試験板を90度引きはがし法の治具にとり付け
る。治具は下部チヤツクに、試験片の一端を上部
チヤツクにはさみ、シヨツパー型引張試験機の振
子を自由にして300mm/minの速さで連続して引
き剥がし、約20mm剥れる毎に計4回の荷重を読み
取り平均値を求める。そして3回の試験結果の平
均値を接着力とする。
レオメーター抵抗値:実施例、比較例及び参考
例の含水ゲル組成物を用いて、試験のために、大
きさ約6cm角、厚さ10mmのシート状含水ゲル体を
作る。
このゲル体をレオメーター(富士理科工業社製
RUD−J型)の試験台上に設置したラボジヤツ
キ上に置き、レオメーター本体と連動する棒に連
設された直径10mmφ、厚さ3mmの測定端子デイス
クと試料表面が接するようにラボジヤツキを上昇
させて零点調整をする。次にラボジヤツキを正確
に5mm下降させた後に、レオメーター試料台の上
昇距離が10mmとなる様にセツトする。次にレオメ
ーターと連動する様にレコーダーをセツトし、50
mm/minの速さで試料台を上昇させ圧縮距輪と測
定端子にかかる応力の関係を記録させる。この記
録紙上の5mm圧縮時の応力を抵抗値とする。
糊のこり:被験者(10人)に試験片を6時間貼
り付けた後、剥して皮膚面へのゲルの残留を目視
により判定する。
○:全く残留がみられない。
△:僅かに残留がみられる。
×:残留が多い。
温水浸漬試験:試料ゲルシートより約2cm角の
試験片を取り40℃の温水中に1時間浸漬した後に
ゲルの状態を目視で判定する。
この発明の実施例においては、主としてサリチ
ル酸メチル系の薬物について示したが、他の薬物
としてコルチコステロイド類、抗生物質、麻酔
剤、抗ヒスタミン剤、抗菌性物質、他の鎮痛消炎
剤、抗真菌剤、角者軟化剤、ビタミン剤、けいれ
ん止め剤等の外皮用薬、および鎮静剤、抗マラリ
ア剤、解熱剤、神経安定剤、降血圧剤、挾心症予
防剤、催眠剤等の全身薬についても適用可能であ
る。[Table] In Comparative Examples 1 and 2 in Table 1, the polyepoxide used as a crosslinking component used in the formulation of Examples 1 and 2 was not added. Reference example 1 includes 15 parts of gelatin, 4 parts of sodium polyacrylate (average degree of polymerization 30,000 to 66,000), 10 parts of glycerin, and water.
36 parts, methyl salicylate 2 parts, dl-camphor-2
It is a water-containing material consisting of 1 part of l-menthol and 2 parts of glycerin diglycidyl ether, and Reference Example 2 is made of sodium carboxymethyl cellulose.
4.8 parts methylcellulose 2.4 parts, sodium polyacrylate 3.8 parts, gelatin 5.9 parts, glycerin 35.6 parts.
47.5 parts of water, 1.3 parts of l-menthol, dl-camphor
It is a water-containing material consisting of 1 part of methyl salicylate, 2 parts of methyl salicylate, and 1.2 parts of thymol. Test method in Table 1 90 degree peel adhesive strength: Width 5 cm from the test gel sheet,
Take three test pieces approximately 20 cm in length, place the hydrous gel surface on a Bakelite plate whose surface has been thoroughly cleaned with ethyl alcohol, and roll an 850 g pressure roll 300 mm/
After crimping once at a speed of min. and leaving it for 30 minutes, attach the test plate to a 90 degree peeling jig. The jig was placed in the lower chuck, and one end of the test piece was placed in the upper chuck, and the pendulum of the chopper type tensile tester was set free, and the test pieces were continuously peeled off at a speed of 300 mm/min, a total of 4 times each time about 20 mm was peeled off. Read the load and find the average value. Then, the average value of the three test results is taken as the adhesive strength. Rheometer resistance value: Using the hydrogel compositions of Examples, Comparative Examples, and Reference Examples, a sheet-shaped hydrogel body having a size of approximately 6 cm square and a thickness of 10 mm is prepared for testing. This gel body was measured using a rheometer (manufactured by Fuji Rika Kogyo Co., Ltd.).
RUD-J type) placed on the lab jack installed on the test stand, and raised the lab jack so that the sample surface was in contact with the measurement terminal disk with a diameter of 10 mmφ and thickness of 3 mm attached to a rod that interlocked with the rheometer main body. Adjust the zero point. Next, after lowering the lab jack accurately by 5 mm, set the rheometer sample stage so that the rising distance is 10 mm. Next, set the recorder so that it works with the rheometer, and
The sample stage is raised at a speed of mm/min and the relationship between the stress applied to the compression ring and the measurement terminal is recorded. The stress when compressed by 5 mm on this recording paper is defined as the resistance value. Glue residue: After applying the test piece to the test subjects (10 people) for 6 hours, remove it and visually judge whether the gel remains on the skin surface. ○: No residue observed at all. △: Slight residue is observed. ×: There is a lot of residue. Warm water immersion test: Take a test piece approximately 2 cm square from the sample gel sheet, immerse it in 40°C warm water for 1 hour, and then visually judge the state of the gel. In the examples of this invention, methyl salicylate drugs are mainly shown, but other drugs include corticosteroids, antibiotics, anesthetics, antihistamines, antibacterial substances, other analgesic anti-inflammatory agents, antifungal agents, Applies to dermatological drugs such as emollients, vitamins, and antispasmodics, as well as systemic drugs such as sedatives, antimalarials, antipyretics, nerve stabilizers, antihypertensives, anticholinergic agents, and hypnotics. It is possible.
Claims (1)
を有するアルキル基の炭素数が4以下の(メタ)
アクリル酸アルキルエステル系共重合体と、水
と、分子内に2個以上のグリシジルエーテル基を
含有するポリエポキシドとを必須成分とし、治療
を目的として貼付または被覆状態で用いられる架
橋型含水ゲル。 2 特許請求の範囲該1項記載の架橋型含水ゲル
において、該含水ゲルに薬物を添加したもの。 3 特許請求の範囲第1〜2項の各れかに記載の
架橋型含水ゲルにおいて、該含水ゲルの含水率が
約15〜80重量%のもの。[Scope of Claims] 1. A (meth) alkyl group having a functional group capable of reacting with an epoxy group in which the number of carbon atoms is 4 or less
A crosslinked hydrogel containing an acrylic acid alkyl ester copolymer, water, and a polyepoxide containing two or more glycidyl ether groups in its molecule as essential components, and is used in a patched or covered state for therapeutic purposes. 2. A cross-linked hydrogel according to claim 1, in which a drug is added to the hydrogel. 3. The crosslinked hydrogel according to any one of claims 1 to 2, which has a water content of about 15 to 80% by weight.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP5908080A JPS56154421A (en) | 1980-05-01 | 1980-05-01 | Crosslinkable aqueous gel used in medical treatment |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP5908080A JPS56154421A (en) | 1980-05-01 | 1980-05-01 | Crosslinkable aqueous gel used in medical treatment |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS56154421A JPS56154421A (en) | 1981-11-30 |
JPH0129765B2 true JPH0129765B2 (en) | 1989-06-14 |
Family
ID=13103006
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP5908080A Granted JPS56154421A (en) | 1980-05-01 | 1980-05-01 | Crosslinkable aqueous gel used in medical treatment |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS56154421A (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7887842B2 (en) * | 2003-02-07 | 2011-02-15 | Teikoku Pharma Usa, Inc. | Methods of administering a dermatological agent to a subject |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5082143A (en) * | 1973-06-20 | 1975-07-03 | ||
JPS5434390A (en) * | 1977-08-24 | 1979-03-13 | Nippon Jiyunyaku Kk | Preparation of selffcrosslinking emulsion polymer |
-
1980
- 1980-05-01 JP JP5908080A patent/JPS56154421A/en active Granted
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5082143A (en) * | 1973-06-20 | 1975-07-03 | ||
JPS5434390A (en) * | 1977-08-24 | 1979-03-13 | Nippon Jiyunyaku Kk | Preparation of selffcrosslinking emulsion polymer |
Also Published As
Publication number | Publication date |
---|---|
JPS56154421A (en) | 1981-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4989607A (en) | Highly conductive non-stringy adhesive hydrophilic gels and medical electrode assemblies manufactured therefrom | |
US5276079A (en) | Pressure-sensitive poly(n-vinyl lactam) adhesive composition and method for producing and using same | |
AU652717B2 (en) | Non-stringy adhesive hydrophilic gels | |
EP0062682B1 (en) | Adhesive preparation for heart disease and process for its preparation | |
US5674275A (en) | Polyacrylate and polymethacrylate ester based hydrogel adhesives | |
JP2970772B2 (en) | Transdermal gel preparation | |
JP2849950B2 (en) | Transdermal formulation | |
JPH0580514B2 (en) | ||
CA2146286A1 (en) | Polyacrylate and polymethacrylate ester based hydrogel adhesives | |
US4778786A (en) | Composition for transdermal drug delivery | |
JP2006290858A (en) | Pressure sensitive adhesive composition for the skin, pressure sensitive adhesive composition for bioelectrode, pressure sensitive adhesive composition for percutaneous absorption, tape for the skin, bioelectrode, and percutaneous absorbing preparation | |
JPH0331163B2 (en) | ||
JPS60123417A (en) | Drug delivery member | |
JPS63246325A (en) | Nitroglycerin plasta and its production | |
JPH0129765B2 (en) | ||
JP3554573B2 (en) | Aspirin-containing transdermal preparation | |
JPH0152362B2 (en) | ||
EP0196632B1 (en) | Composition for transdermal drug delivery | |
JPH10500158A (en) | Composite pressure-sensitive hydrophilic adhesive and method for producing the same | |
JPH0339485B2 (en) | ||
JPH0339488B2 (en) | ||
JP2022543537A (en) | Acrylic polymer and adhesive composition | |
JPH046164B2 (en) | ||
JPH0335284B2 (en) | ||
JPH06145051A (en) | Patch for application before treatment of centesis and method for alleviating pain during centesis |